Abstract Background. Observational studies suggest that people who consume more fruits and vegetables containing beta carotene have somewhat lower risks of cancer and cardiovascular disease, and earlier basic research suggested plausible mechanisms. Because large randomized trials of long duration were necessary to test this hypothesis directly, we conducted a trial of beta carotene supplementation.
O BSERVATIONAL epidemiologic studies suggest that people who consume higher dietary levels of fruits and vegetables containing beta carotene have a lower risk of certain types of cancer 1, 2 and cardiovascular disease, 3 and basic research suggests plausible mechanisms. [4] [5] [6] It is difficult to determine from observational studies, however, whether the apparent benefits are due to beta carotene itself, other nutrients in beta carotenerich foods, other dietary habits, or other, nondietary lifestyle characteristics. 7 Long-term, large, randomized trials can provide a direct test of the efficacy of beta carotene in the prevention of cancer or cardiovascular disease. 8 For cancer, such trials should ideally last longer than the latency period (at least 5 to 10 years) of many types of cancer. A trial lasting 10 or more years could allow a sufficient period of latency and an adequate number of cancers for the detection of even a small reduction in overall risk due to supplementation with beta carotene.
Two large, randomized, placebo-controlled trials in well-nourished populations (primarily cigarette smokers) have been reported. The Alpha-Tocopherol, Beta Carotene (ATBC) Cancer Prevention Study, a placebocontrolled trial, assigned 29,000 Finnish male smokers to receive beta carotene, vitamin E, both active agents, or neither, for an average of six years. 9 The BetaCarotene and Retinol Efficacy Trial (CARET) enrolled 18,000 men and women at high risk for lung cancer because of a history of cigarette smoking or occupational exposure to asbestos; this trial evaluated combined treatment with beta carotene and retinol for an average of less than four years. 10 Both studies found no benefits of such supplementation in terms of the incidence of cancer or cardiovascular disease; indeed, both found somewhat higher rates of lung cancer and cardiovascular disease among subjects given beta carotene. The estimated excess risks were small, and it remains unclear whether beta carotene was truly harmful. Moreover, since the duration of these studies was relatively short, they leave open the possibility that benefit, especially in terms of cancer, would become evident with longer treatment and follow-up. 11 In this report, we describe the findings of the beta carotene component of the Physicians' Health Study, a randomized trial in which 22,071 U.S. male physicians were treated and followed for an average of 12 years.
M ETHODS

Study Design
The Physicians' Health Study is a randomized, double-blind, placebo-controlled trial with a two-by-two factorial design that tested aspirin and beta carotene in the primary prevention of cardiovascular disease and cancer. The methods of the study have been described in detail previously. 12, 13 Briefly, 22,071 U.S. male physicians, who were 40 to 84 years of age in 1982 and had no history of cancer (except nonmelanoma skin cancer), myocardial infarction, stroke, or transient cerebral ischemia, were randomly assigned to one of four groups: aspirin (325 mg on alternate days [Bufferin, provided by BristolMyers]) plus beta carotene placebo, beta carotene (50 mg on alternate days [Lurotin, provided by BASF Corporation]) plus aspirin placebo, both active agents, or both placebos. Informed consent was obtained from all participants, and the research protocol was reviewed and approved by the institutional review board at Brigham and Women's Hospital in Boston. At base line in 1982, 11 percent of the physicians were current smokers and 39 percent were former smokers.
The randomized aspirin component of the study was terminated early, on January 25, 1988 , on the advice of the external data-monitoring board, primarily because there was a statistically significant (P Ͻ 0.001) 44 percent reduction in the risk of a first myocardial infarction in the aspirin group. 12, 13 The randomized beta carotene component continued uninterrupted until its scheduled termination, on December 31, 1995. A total of 11,036 physicians were assigned at random to receive beta carotene and 11,035 to receive beta carotene placebo. Data on all 22,071 participants were analyzed according to their treatment assignment, regardless of subsequent compliance.
Study Treatment and Follow-up
Every six months for the first year and annually thereafter, the participants were sent monthly calendar packs (provided by BristolMyers from 1982 through 1988) that contained red capsules (beta carotene or placebo) for even-numbered days and white pills (aspirin or placebo) for odd-numbered days. After January 25, 1988, physicians could request that their white pills be active aspirin, but the beta carotene component of the trial remained randomized, doubleblind, and placebo-controlled until December 31, 1995. Participants were sent brief yearly follow-up questionnaires, asking about their compliance with the treatment regimen and about the occurrence of any relevant events. After three mailed requests for follow-up information, the participants were contacted by telephone. When the randomized aspirin study was terminated, participants had been treated for an average of five years; 99.7 percent were providing follow-up with respect to morbidity by mailed questionnaire or telephone interview; follow-up for mortality was 100 percent complete. At the time, 85 percent of the beta carotene group was still taking the study pills; in the placebo group, 4 percent reported taking beta carotene or vitamin A supplements.
By the end of 1995, participants had been taking beta carotene or placebo for an average of 12 years (range, 11.6 to 14.2). At the end of 11 years of follow-up (the last year completed for all participants), 99.2 percent were still providing information on morbidity; follow-up for mortality was 99.99 percent complete. In both the beta carotene group and the placebo group, 80 percent of participants were still taking the study pills, with an average compliance of over 97 percent. The remaining 20 percent were not taking any study pills. Thus, in the beta carotene group, 78 percent of the study pills were reported as still being taken; in the placebo group, 6 percent of the physicians reported taking supplemental beta carotene or vitamin A.
To assess the validity of reported compliance with the assigned treatment, we measured plasma beta carotene concentrations in blood obtained at unannounced visits to study participants' offices in three geographic areas.
14 Those assigned to receive beta carotene had significantly higher concentrations than those given placebo (1.2 vs. 0.3 mg per liter [2.24 vs. 0.56 mmol per liter], P Ͻ 0.001). Only one participant assigned to the placebo group had a plasma beta carotene concentration equal to the mean in the beta carotene group, and he reported taking a beta carotene supplement. In addition, there was a highly significant correlation between the subjects' reports of their compliance with the study regimen and their plasma beta carotene concentrations (r ϭ 0.69, P Ͻ 0.001).
Confirmation of End Points
When a relevant end point was reported, we requested written consent to review the participant's medical records. Details were requested from hospitals and treating physicians. Reports of malignant neoplasms, cardiovascular disease, or death were considered refuted or confirmed only after the examination of all available information by an end-points committee made up of two internists, a cardiologist, and a neurologist, all of whom were blinded to the treatment assignments. When written consent or the relevant records could not be obtained, a reported event was not classified as confirmed. So far, medical records have been obtained and reviewed for over 95 percent of the events reported as of October 24, 1995. Unless otherwise indicated, the analyses reported here for the main end points include all events that have not been refuted by review of the medical records, since most of the events reported by participating doctors will eventually be confirmed. In fact, 95 percent of the events that have not been refuted have so far been confirmed. Furthermore, all analyses were repeated with only confirmed events included, and the results were virtually identical to those without the exclusion of events not yet confirmed for all time periods. (We have also presented data on major end points based only on confirmed events.)
Reported cases of malignant neoplasm required confirmation by pathology report. Diagnoses of nonfatal myocardial infarction were confirmed with the use of World Health Organization criteria. 15 Nonfatal stroke was defined as a typical neurologic deficit, either sudden or rapid in onset, that lasted more than 24 hours and was attributed to a cerebrovascular event. Death due to a cardiovascular cause was confirmed by convincing evidence of a cardiovascular mechanism from available sources, including death certificates, hospital records, and (for death outside the hospital) observers' accounts.
The primary end point for the beta carotene component of the trial was any type of malignant neoplasm except nonmelanoma skin cancer. Malignant neoplasms diagnosed within two years of randomization were considered separately, as specified in advance, since many of these may have been present as preclinical disease at base line. For the end points of malignant neoplasm, myocardial infarction, and stroke, only the first end point in each category reported by a participant was counted. For example, if a participant reported having a malignant neoplasm, no subsequently diagnosed case was counted in the analyses of total malignant neoplasms, although that physician continued to be followed for cardiovascular disease and mortality.
Statistical Analysis
The Cox proportional-hazards model was used to estimate the relative risk of an end point among those randomly assigned to beta carotene as compared with those assigned to placebo, with adjustment for age at base line and, during the first five years, random assignment to the aspirin or placebo group in the aspirin component of the trial. Controlling for assignment with respect to aspirin did not change the estimates of relative risk, nor did the participants' assignment with respect to aspirin materially alter the effect of beta carotene on any of the primary end points. For each relative risk, the 95 percent confidence interval and two-sided P value were calculated. As expected in a large, randomized trial, the distribution of base-line characteristics was virtually identical in the beta carotene and placebo groups.
16
R ESULTS
Malignant Neoplasms
As shown in Table 1 and Figure 1 , after an average of 12 years of treatment and follow-up, there was no significant effect of beta carotene on the primary end point of all cases of malignant neoplasm (1273 cases in the beta carotene group vs. 1293 in the placebo group; relative risk, 0.98; 95 percent confidence interval, 0.91 to 1.06). When the period of risk was subdivided according to years of follow-up, there was still no statistically significant benefit or harm, even after five or more years of treatment and follow-up. When these analyses were repeated with only confirmed events included, the relative risks were virtually identical for all time periods, including five or more years (Table 1) .
Similarly, there was no statistically significant benefit or harm due to beta carotene with respect to cancer of the lung (82 cases in the beta carotene group vs. 88 in the placebo group), colon and rectum (167 vs. 174), prostate (520 vs. 527), stomach (19 vs. 21) , pancreas (29 vs. 21), or brain (25 vs. 31) or for melanoma (64 vs. 73), leukemia (35 vs. 42), or lymphoma (86 vs. 80). With respect to bladder cancer, there were 62 cases in the beta carotene group and 41 in the placebo group; with respect to thyroid cancer, there were 16 in the beta carotene group and 2 in the placebo group. After adjustment for multiple comparisons, however, neither of these differences was statistically significant at the 0.05 level. In fact, previous observational studies of bladder cancer 17 and thyroid cancer 18 had suggested a possible protective effect of foods rich in beta carotene. There was no significant effect of beta carotene on the number of deaths due to all malignant neoplasms (386 vs. 380) ( Table 1) or deaths due to lung cancer (63 vs. 62).
Cardiovascular Events
There was no statistically significant benefit or harm from beta carotene with respect to the number of myocardial infarctions (468 in the beta carotene group vs. 489 in the placebo group), strokes (367 vs. 382), deaths due to cardiovascular causes (338 vs. 313), all important cardiovascular events (967 vs. 972), or deaths from all causes (979 vs. 968) ( Table 2 and Fig. 1 ). Moreover, there was no significant trend toward greater benefit or harm with an increasing duration of treatment, even five or more years after randomization.
Effects among Smokers
Although the ATBC and CARET studies raised the possibility that beta carotene might cause harm in current smokers, the relative risk of all malignant neoplasms for participants in the Physicians' Health Study who were smokers in 1982 was 1.05 for the beta carotene group as compared with the placebo group (95 percent confidence interval, 0.86 to 1.28); that of lung cancer, 0.90 (95 percent confidence interval, 0.58 to 1.40); that of death from cardiovascular causes, 1.13 (95 percent confidence interval, 0.80 to 1.61); and that of death from all causes, 1.05 (95 percent confidence interval, 0.86 to 1.29) ( Table 3) .
Side Effects
During 12 years of treatment and follow-up, no major side effects were significantly associated with assignment to beta carotene supplementation. Minor side effects included statistically significant increases in reports of yellowing of the skin (which occurred in 1745 subjects in the beta carotene group as compared with 1535 in the placebo group) and minor gastrointestinal symptoms, such as belching associated with the red capsules (275 vs. 124), findings described previously in studies of beta carotene in this dose and formulation.
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D ISCUSSION
This large-scale, randomized trial among apparently healthy, well-nourished men demonstrated no statistically significant benefit or harm due to 12 years of beta carotene supplementation in terms of malignant neoplasms, cardiovascular disease, or death. Because of the long duration of the trial, these findings are particularly informative, and the large sample and narrow confidence intervals exclude even a small overall benefit or harm due to beta carotene with a high degree of assurance. However, for individual end points such as stroke, myocardial infarction, and particular types of cancer, the confidence intervals are wider and do not preclude the possibility of a small absolute effect. In view of the slow development of many cancers, follow-up in this and the other trials of beta carotene will continue even though treatment has ceased, in case any benefits or hazards become clear later.
Factors that could, at least in theory, have produced a false finding of no benefit or harm include an inadequate dose of beta carotene or poor compliance with the assigned treatment. The dose of beta carotene used in the trial, however, placed participants in the top few percentiles of the general population with respect to usual intake, while minimizing noticeable yellowing of the skin. In our studies of the bioavailability of beta carotene, this alternate-day dosage and formulation increased plasma beta carotene concentrations approximately fourfold. 14 This intake is above the level of dietary beta carotene consumption that is associated with benefit in observational studies and is roughly equivalent in effects on blood levels to about two carrots a day (as compared with about three carrots a day in the ATBC study and four carrots a day in CARET). Poor compliance (either the failure of those assigned to receive beta carotene to adhere to the study treatment or the use of beta carotene supplements by those assigned to the placebo group) is not a plausible explanation for our findings, since there was 85 percent compliance with beta carotene treatment after 5 years and compliance was still 78 percent after 12 years; in addition, the use of beta carotene or vitamin A supplements was reported by only 6 percent of the placebo group even by the end of the trial.
Observation bias is an unlikely explanation for our findings, since reports of end points were refuted or confirmed by a committee of physicians blinded to the participants' treatment assignments, and separate analyses of unrefuted and confirmed events gave virtually identical results.
Two other large trials of beta carotene or combination treatments incorporating beta carotene in wellnourished populations 9, 10 and one in a poorly nourished population 20 have been conducted, but they involved only four to six years of treatment, with no post-treatment results yet available. One reported a significant benefit of beta carotene, 20 whereas two found that it had significant adverse effects with respect to cancer rates in the first few years. 9, 10 In our trial, however, we found no evidence either of benefit or of increased risk associated with beta carotene, even in the later period. There were 996 malignant neoplasms diagnosed five or more years after randomization in the beta carotene group, and 1027 in the placebo group. The absence of a significant effect on cancer rates in the later part of the study suggests that beta carotene supplements are likely to have little or no effect on cancer rates in the first few years after randomization.
Furthermore, the finding in the two other large trials of possible harm among smokers given beta carotene 9, 10 is not consistent with the results of observational studies, which have, in fact, suggested that fruits and vegetables rich in beta carotene may prevent lung cancer 21, 22 and coronary heart disease 23 in smokers. Although, in the Physicians' Health Study, participants who were cigarette smokers in 1982 represented only 11 percent and former smokers only 39 percent of the total, those assigned to receive beta carotene supplements had no statistically significant decrease or increase in risks.
In addition to these four large-scale trials, two smaller trials of beta carotene supplementation in the prevention of recurrent skin cancer 19 and colon polyps 24 have also been completed. Both found that beta carotene had no significant benefit or harm. Our chief aim in this trial was to provide either a definitive positive result or an informative null finding on which to base rational public health recommendations. The need for such reliable evidence is underscored by the fact that a substantial amount of money is spent on beta carotene supplements by the general public. Even though beta carotene is ineffective in preventing cancer and cardiovascular disease, other micronutrients may not be. For example, vitamin E supplementation remains promising as a preventive intervention. 3, 23, 25 It is currently being tested in a large-scale primary-prevention trial among women 26 and in several trials among people at high risk. 27 For beta carotene, however, the results of this trial indicate that supplementation is not effective in preventing cancer or cardiovascular disease in apparently healthy, well-nourished men. 
